Abstract
Southern Africa is burdened with Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (M.tuberculosis) infections as well as conditions of iron (Fe) overload. Highly Active Antiretroviral Therapy (HAART) is used to treat HIV-infection, many drugs exist for the treatment of tuberculosis (new solutions are also being sought because of the existence of multi drug resistant strains of M.tuberculosis) and Fe chelators are commonly used to treat Fe overload. Chelators have also been shown to inhibit the multiplication of numerous microorganisms and hence there are publications suggesting a role for chelators like desferrioxamine (DFO) in the dual treatment of microorganism infection and excess iron. Excess iron fuels pathogen survival which in turn lowers host cell functionality (manifested as altered proliferation, cytokine secretion, etc); withholding iron (via a chelator) reverses the process, even more so when the cells are chelated for longer periods of time. Chelation with DFO is reviewed here by commenting on its immunomodulatory effect.
Keywords: Desferrioxamine, HIV, M.tuberculosis, iron, immunomodulatory, immune restoration
Current Pharmaceutical Design
Title: Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Volume: 15 Issue: 11
Author(s): A. Williams and D. Meyer
Affiliation:
Keywords: Desferrioxamine, HIV, M.tuberculosis, iron, immunomodulatory, immune restoration
Abstract: Southern Africa is burdened with Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (M.tuberculosis) infections as well as conditions of iron (Fe) overload. Highly Active Antiretroviral Therapy (HAART) is used to treat HIV-infection, many drugs exist for the treatment of tuberculosis (new solutions are also being sought because of the existence of multi drug resistant strains of M.tuberculosis) and Fe chelators are commonly used to treat Fe overload. Chelators have also been shown to inhibit the multiplication of numerous microorganisms and hence there are publications suggesting a role for chelators like desferrioxamine (DFO) in the dual treatment of microorganism infection and excess iron. Excess iron fuels pathogen survival which in turn lowers host cell functionality (manifested as altered proliferation, cytokine secretion, etc); withholding iron (via a chelator) reverses the process, even more so when the cells are chelated for longer periods of time. Chelation with DFO is reviewed here by commenting on its immunomodulatory effect.
Export Options
About this article
Cite this article as:
Williams A. and Meyer D., Desferrioxamine as Immunomodulatory Agent During Microorganism Infection, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846801
DOI https://dx.doi.org/10.2174/138161209787846801 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Abelson Tyrosine-Protein Kinase 1 as Principal Target for Drug Discovery Against Leukemias. Role of the Current Computer-Aided Drug Design Methodologies
Current Topics in Medicinal Chemistry Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents Recent Advances of 2-Quinolone-Based Derivatives as Anti-Tubercular Agents
Anti-Infective Agents Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Toxic Effects of Aflatoxin B1 on Embryonic Development of Zebrafish (Danio rerio): Potential Activity of Piceatannol Encapsulated Chitosan/poly (Lactic Acid) Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Tuberculosis: Challenges to Improve the Treatment
Current Clinical Pharmacology Cystic Fibrosis and the Innate Immune System: Therapeutic Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Synthesis, Characterization, Biological Activity and Voltammetric Behavior and Determination of Cefaclor Metal Complexes
Current Analytical Chemistry Design, Synthesis and In Vitro Antimalarial Evaluation of New Quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery iMethylK-PseAAC: Improving Accuracy of Lysine Methylation Sites Identification by Incorporating Statistical Moments and Position Relative Features into General PseAAC via Chou’s 5-steps Rule
Current Genomics Antibiotic Properties of Novel Synthetic Temporin A Analogs and a Cecropin A-Temporin A Hybrid Peptide
Protein & Peptide Letters Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Visual and Quantitative Assessment of COVID-19 Pneumonia on Chest CT: The Relationship with Disease Severity and Clinical Findings
Current Medical Imaging Targeted Vaccine Adjuvants Based on Modified Cholera Toxin
Current Molecular Medicine Synthesis and Antitubercular Screening of Some Novel 4H-1,4- Benzothiazines and their Sulfones Under Environment Benign Solvent Free Conditions as Future Anti-Tubercular Agents
Combinatorial Chemistry & High Throughput Screening Synthesis and Antimicrobial Activity of N,N-Bis(2-hydroxylbenzyl)-1,2- ethanediamine Derivatives
Letters in Drug Design & Discovery Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews